Migea (Tolfenamic Acid)

Tolfenamic acid, the active ingredient in Migea, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as an oral tablet for oral use. It treats mild to moderate pain and inflammatory conditions such as rheumatoid arthritis, osteoarthritis and dysmenorrhea in adults.

GNH USA supplies Migea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Migea, a non‑steroidal anti‑inflammatory drug, is used for several inflammatory and pain‑related conditions.

Rheumatoid arthritis: reduces joint inflammation and pain, improving mobility. Osteoarthritis: alleviates chronic joint discomfort and swelling. Dysmenorrhea: provides analgesic relief of menstrual cramps.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia, or abdominal pain. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Skin rash or mild pruritus. - Elevated liver enzymes (asymptomatic).

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Hepatic injury: jaundice or hepatitis. - Renal impairment or acute kidney injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Anaphylactic or anaphylactoid reactions. - Blood dyscrasias: agranulocytosis or thrombocytopenia.

Before prescribing Migea, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

Assess renal function: obtain baseline kidney tests and adjust use in renal impairment. Evaluate hepatic status: monitor liver enzymes, especially in patients with existing liver disease. Check cardiovascular risk: use cautiously in patients with hypertension or heart disease. Avoid in active peptic ulcer disease: consider alternative therapy due to ulcer risk. Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Tolfenamic acid can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Corticosteroids: heightened risk of ulceration and bleeding.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: may enhance nephrotoxic potential. - Lithium: NSAIDs can raise lithium serum levels, requiring monitoring.